NCT02323646.

Trial name or title	A Phase 2 Study to Evaluate the Safety and Efficacy of Proellex (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids
Methods	Randomised controlled trial
Participants	Premenopausal women with symptomatic uterine fibroids
Interventions	Two vaginal doses of Proellex (6 mg vs 12 mg vs placebo) administered for up to 2 courses of treatment (18 weeks each), each separated by an off‐drug interval (ODI)
Outcomes	Percentage of participants who become amenorrhoeic after 1 course of treatment (6 months)
Starting date	December 2014
Contact information	Repros Therapeutics Inc
Notes